What's Happening?
Enable Injections, a healthcare innovation company based in Cincinnati, has announced a $30 million investment from Sanofi. This funding is aimed at accelerating the manufacturing capabilities of Enable's
enFuse® On-Body Delivery System (OBDS), a wearable technology designed to deliver large volumes of pharmaceutical and biologic therapeutics subcutaneously. The investment will enhance Enable's manufacturing build-out, strengthen its supply chain, and drive commercial growth. The enFuse system is noted for its convenience, featuring a small, hidden, and retractable needle that administers medication with the click of a button. This system was part of Sanofi's clinical studies for multiple myeloma treatments, and its use is currently under regulatory review. Enable Injections has previously raised significant funds, including a $215 million Series C financing in 2022, and plans to expand its manufacturing facilities in Ohio.
Why It's Important?
The investment from Sanofi underscores the growing demand for innovative drug delivery systems that improve patient convenience and treatment outcomes. Enable Injections' enFuse system represents a significant advancement in the administration of large-volume injectable therapies, which can be particularly beneficial for patients with chronic conditions requiring regular medication. By enhancing its manufacturing capabilities, Enable is poised to meet the increasing demand for its technology, potentially transforming the way biologic therapeutics are administered. This development could lead to broader adoption of wearable drug delivery systems, impacting the pharmaceutical industry by offering more patient-friendly treatment options and potentially reducing healthcare costs through improved adherence and outcomes.
What's Next?
Enable Injections is expected to continue expanding its manufacturing and commercial capabilities, with plans for a new Manufacturing Center of Excellence in Ohio. The company is also working with pharmaceutical partners to conduct clinical trials and prepare for the joint commercial launch of therapies using the enFuse system. Regulatory reviews of the enFuse system's use in specific treatments are ongoing, and successful approvals could further solidify Enable's position in the market. As the company scales up its operations, it may attract additional investments and partnerships, further driving innovation in the field of drug delivery systems.
